This activity will assist physician assistants (PAs) who wish to apply for a waiver to prescribe buprenorphine for the treatment of opioid use disorders.
In accordance with the Comprehensive Addiction and Recovery Act (CARA), PAs must complete 24 hours of specialized training to prescribe buprenorphine, one of three medications approved by the FDA for the treatment of opioid use disorder. This activity will allow PAs to fulfill the 16 hour portion of the 24 hour MAT waiver training requirement.
At the conclusion of this activity, learners should be able to:
- Provide information about the pharmacology and clinical use of buprenorphine
- Provide information on other approved antagonist and agonist medications to treat opioid use disorder
- Provide resources needed to set up office-based treatment of opioid use disorder using buprenorphine
Fee: No cost
AAPA Credit Designation Statement Enduring Material: American Academy of Addiction Psychiatry has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 16 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Method of participation in the activity: To be awarded a maximum of AAPA Category 1 CME credits and a Certificate of Completion you must:
- Review 16 training modules (16 hours) provided in this activity.
- Earn a passing score of 75% on each of the module’s post-tests.
- Complete a final evaluation and follow instructions at the end of the course regarding how to retrieve your Certificate of Completion as well as your continuing credit certificate*.
*Credit will not be awarded unless all components of the program are completed. Partial credit will not be awarded.
Disclosures: AAAP's CME program aims to provide educational information that is balanced, independent, objective and free of bias and based on evidence. In order to resolve any identified Conflicts of Interest, disclosure information from all series planners and speakers is provided during the planning process to ensure resolution of any identified conflicts. The following PCSS-MAT AAAP staff and CPD Committee members have reported that they have no commercial relationships relevant to the content of this activity to disclose: Dean Krahn, MD, Michael Goedde, MD, Thomas Penders, MD, Alan Gordon, MD, Oliveria Bugunovic, MD, Margi Kotz, MD, Kathryn Cates-Wessel, Justina Andonian and Miriam Giles. Kevin Sevarino, MD owns a small amount of stock in GSK. Content Developers for this 16 hour course disclose the following: https://30qkon2g8eif8wrj03zeh0...
Disclosure of Unlabeled Medication Use:Faculty have been advised that any recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. AAAP has determined that all scientific research referred to, reported, or used in this course conforms to the generally accepted standards of experimental design, data collection, and analysis.
Support for the Program:
Funding for this initiative was made possible (in part) by grant no. 5U79TI026556 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.